BioLineRx Enters into “At-The-Market” Offering Agreement with Stifel, Nicolaus & Company
The ATM program does not constitute an immediate sale of the Company’s ADSs. The program permits the Company to raise capital at the times and in amounts deemed suitable by management. The Company is not required to sell any ADSs at any time. The Company intends to use net proceeds from the ATM facility, if any, to fund clinical trials and for working capital and general corporate purposes.
“We believe that an ATM program is an efficient approach to raise
capital, if necessary, on an as needed basis. It is designed to enable
operational flexibility,” said Dr.
ATM sales, if any, will be made pursuant to a prospectus supplement,
This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, any of the ADSs or Ordinary Shares of the Company, nor shall there be any sale of these ADSs or Ordinary Shares of the Company, in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
BioLineRx is a publicly-traded biopharmaceutical development company.
BioLineRx is dedicated to building a portfolio of products for unmet
medical needs or with advantages over currently available therapies.
BioLineRx’s current portfolio consists of seven clinical stage
candidates: BL-1040, for prevention of pathological cardiac remodeling
following a myocardial infarction, which has been out-licensed to
BioLineRx’s business model is based on acquiring molecules mainly from
biotechnological incubators and academic institutions. The Company
performs feasibility assessment studies and development through
pre-clinical and clinical stages, with partial funding from the Israeli
Various statements in this release concerning BioLineRx’s future
expectations constitute “forward-looking statements” within the
meaning of the Private Securities Litigation Reform Act of 1995. These
statements include words such as “may,” “expects,” “anticipates,”
“believes,” and “intends,” and describe opinions about future
events. These forward-looking statements involve known and unknown risks
and uncertainties that may cause the actual results, performance or
achievements of BioLineRx to be materially different from any
future results, performance or achievements expressed or implied by
such forward-looking statements. Some of these risks are: changes in
relationships with collaborators; the impact of competitive
products and technological changes; risks relating to the development
of new products; and the ability to implement technological
improvements. These and other factors are more fully discussed in
the “Risk Factors” section of BioLineRx’s most recent annual
report on Form 20-F filed with the